Alpha 2.0
Login Register
» Authors » A Omlin

A Omlin

Explore the profile of A Omlin including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 30
Citations 740
Followers 0
Related Specialties
Oncology
Urology
Critical Care
Top 10 Co-Authors
G Attard
S Gillessen
J S de Bono
C Pezaro
C Parker
D Bianchini
D Lorente
R Ferraldeschi
D Mukherji
N Tunariu
Published In
Ann Oncol
Br J Cancer
Eur Urol
Eur J Cancer
Lung Cancer
Affiliations
Soon will be listed here.
Recent Articles
1.
How to read a next-generation sequencing report-what oncologists need to know
Schmid S, Jochum W, Padberg B, Demmer I, Mertz K, Joerger M, et al.
ESMO Open . 2022 Oct; 7(5):100570. PMID: 36183443
Next-generation sequencing (NGS) of tumor cell-derived DNA/RNA to screen for targetable genomic alterations is now widely available and has become part of routine practice in oncology. NGS testing strategies depend...
2.
Reply to Yu Wei, Yao Zhu, and Dingwei Ye's Letter to the Editor re: Fabio Turco, Andrew Armstrong, Gerhardt Attard, et al. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer...
Turco F, Smith M, Omlin A, Gillessen S
Eur Urol . 2022 Apr; 82(1):e13. PMID: 35469701
No abstract available.
3.
Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003
Clarke N, Ali A, Ingleby F, Hoyle A, Amos C, Attard G, et al.
Ann Oncol . 2020 Feb; 31(3):442. PMID: 32067690
No abstract available.
4.
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
Clarke N, Ali A, Ingleby F, Hoyle A, Amos C, Attard G, et al.
Ann Oncol . 2019 Sep; 30(12):1992-2003. PMID: 31560068
Background: STAMPEDE has previously reported that the use of upfront docetaxel improved overall survival (OS) for metastatic hormone naïve prostate cancer patients starting long-term androgen deprivation therapy. We report on...
5.
When and how to use carboplatin in metastatic castration-resistant prostate cancer?
Omlin A, Gillessen S
Eur J Cancer . 2018 Feb; 92:96-99. PMID: 29395685
No abstract available.
6.
Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer
Pezaro C, Omlin A, Mastris K, Attard G, Beer T, Chi K, et al.
Ann Oncol . 2017 Aug; 28(8):1692-1694. PMID: 28838209
No abstract available.
7.
Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases-analysis of an international multicenter database
Keizman D, Fosboel M, Reichegger H, Peer A, Rosenbaum E, Desax M, et al.
Prostate Cancer Prostatic Dis . 2017 Mar; 20(3):289-293. PMID: 28244493
Background: The imaging response to radium-223 therapy is at present poorly described. We aimed to describe the imaging response to radium-223 treatment. Methods: We retrospectively evaluated the computed tomography (CT)...
8.
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
Gillessen S, Omlin A, Attard G, de Bono J, Efstathiou E, Fizazi K, et al.
Ann Oncol . 2016 May; 30(12):e3. PMID: 27141017
No abstract available.
9.
Anti-tumour activity of platinum compounds in advanced prostate cancer-a systematic literature review
Hager S, Ackermann C, Joerger M, Gillessen S, Omlin A
Ann Oncol . 2016 Apr; 27(6):975-984. PMID: 27052650
Background: For men with advanced castration-resistant prostate cancer (CRPC), several treatment options are available, including androgen receptor (AR) pathway inhibitors (abiraterone acetate, enzalutamide), taxanes (docetaxel, cabazitaxel) and the radionuclide (radium-223)....
10.
Reply to the letter to the editor 'management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015' by Gillessen et al
Gillessen S, Fanti S, Omlin A
Ann Oncol . 2015 Sep; 26(11):2354-5. PMID: 26347101
No abstract available.